Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model

The nasal mucosa is an important arm of the mucosal system since it is often the first point of contact for inhaled antigens. The ineffectiveness of the simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies in appropriate delivery systems and adjuvants. We have evaluated biphasic lipid vesicles as a novel intranasal (i.n.) delivery system (designated as vaccine targeting adjuvant, VTA) containing bacterial antigens and CpG oligode‐oxynucleotides (ODNs). Results show that administration of antigen and CpG ODNs in biphasic lipid vesicles resulted in greater induction of IgA levels in serum (P<0.05) and mucosal antibody responses such as IgA in nasal secretions and lung (P<0.01) after immunization with a combined subcutaneous (s.c.)/i.n. as compared to s.c./s.c. approach. Based on antibody responses, VTA formulations were found to be suitable as delivery systems for antigens and CpG ODNs by the intranasal route, resulting in a Th2‐type of immune response, characterized by IgG1 and IL‐4 production at the systemic level.

[1]  L. Babiuk,et al.  Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. , 2004, Current drug delivery.

[2]  H. McShane,et al.  Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .

[3]  L. Babiuk,et al.  Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix). , 2003, Vaccine.

[4]  M. Baca-Estrada,et al.  Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix) , 2002, The Journal of pharmacy and pharmacology.

[5]  L. Babiuk,et al.  CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. , 2002, Vaccine.

[6]  Y. Barenholz,et al.  Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. , 2002, Vaccine.

[7]  P. Payette,et al.  Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. , 2002, FEMS immunology and medical microbiology.

[8]  Praveen Kumar,et al.  Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. , 2002, Diabetes technology & therapeutics.

[9]  R. Weeratna,et al.  The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. , 2001, Vaccine.

[10]  K. Rosenthal,et al.  Intranasal Immunization with CpG Oligodeoxynucleotides as an Adjuvant Dramatically Increases IgA and Protection Against Herpes Simplex Virus-2 in the Genital Tract1 , 2001, The Journal of Immunology.

[11]  A. Krieg,et al.  Immune effects and mechanisms of action of CpG motifs. , 2000, Vaccine.

[12]  J. Mcghee,et al.  Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.

[13]  H. Davis,et al.  Intranasal Immunization of Mice with CpG DNA Induces Strong Systemic and Mucosal Responses That Are Influenced by Other Mucosal Adjuvants and Antigen Distribution , 2000, Molecular medicine.

[14]  C. Partidos,et al.  Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants , 2000, Infection and Immunity.

[15]  C. Partidos,et al.  Intranasal vaccines: forthcoming challenges. , 2000, Pharmaceutical science & technology today.

[16]  L. Babiuk,et al.  Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. , 2000, Vaccine.

[17]  C. Bennett,et al.  Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. , 2000, The Journal of pharmacology and experimental therapeutics.

[18]  G. Dougan,et al.  Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.

[19]  M. Baca-Estrada,et al.  Dermal and transdermal delivery of protein pharmaceuticals: lipid‐based delivery systems for interferon α , 1999, Biotechnology and applied biochemistry.

[20]  H. Davis,et al.  CpG DNA as mucosal adjuvant. , 1999, Vaccine.

[21]  S. Ståhl,et al.  Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. , 1999, Journal of biotechnology.

[22]  S. Tunca,et al.  Immunoadjuvant action of plasmid DNA in liposomes. , 1999, Vaccine.

[23]  T. Hirst,et al.  Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. , 1999, Immunology today.

[24]  C. Siegrist,et al.  CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Frazer,et al.  Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. , 1998, Virology.

[26]  Y. Sung,et al.  Immuno‐stimulatory effects of bacterial‐derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations , 1998, Immunology.

[27]  O. Leo,et al.  Revisiting the Th1/Th2 Paradigm , 1998, Scandinavian journal of immunology.

[28]  P. Ogra,et al.  Mucosal responses to parenteral and mucosal vaccines. , 1998, Developments in biological standardization.

[29]  L. Babiuk,et al.  Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. , 1997, Vaccine.

[30]  M. Marinaro,et al.  Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. , 1996, The Journal of infectious diseases.

[31]  A. Potter,et al.  Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1 , 1993, Infection and immunity.

[32]  J. Mcghee,et al.  The mucosal immune system: from fundamental concepts to vaccine development. , 1992, Vaccine.